Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis (Q40384471)

From Wikidata

Revision as of 02:24, 14 July 2024 by Twofivesixbot (talk | contribs) (‎Updated Item: rm P2888 pointing to scigraph.springernature.com; site discontinued and merely duplicating DOI)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on December 2005

Language	Label	Description	Also known as
English	Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis	scientific article published on December 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

author name string

Mario I Vega

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sara Huerta-Yepez

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ali R Jazirehi

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Hermes Garban

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Benjamin Bonavida

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8114-8127

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The CD95 type I/type II model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

21 January 2018

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

based on heuristic

inferred from DOI database lookup

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1208954

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40384471&oldid=2203648168"